These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18796514)

  • 1. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity.
    Kotronen A; Lewitt M; Hall K; Brismar K; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4867-72. PubMed ID: 18796514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of liver fat on insulin clearance.
    Kotronen A; Vehkavaara S; Seppälä-Lindroos A; Bergholm R; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1709-15. PubMed ID: 17895288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function.
    Paolisso G; Ammendola S; Del Buono A; Gambardella A; Riondino M; Tagliamonte MR; Rizzo MR; Carella C; Varricchio M
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2204-9. PubMed ID: 9215295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes.
    Llauradó G; Sevastianova K; Sädevirta S; Hakkarainen A; Lundbom N; Orho-Melander M; Groop PH; Forsblom C; Yki-Järvinen H
    J Clin Endocrinol Metab; 2015 Feb; 100(2):607-16. PubMed ID: 25405502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-1 in elderly people: relationships with cardiovascular risk factors, body composition, size at birth, and childhood growth.
    Kajantie E; Fall CH; Seppälä M; Koistinen R; Dunkel L; Ylihärsilä H; Osmond C; Andersson S; Barker DJ; Forsén T; Holt RI; Phillips DI; Eriksson J
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1059-65. PubMed ID: 12629086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
    Benbassat CA; Maki KC; Unterman TG
    J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25).
    López-Bermejo A; Khosravi J; Fernández-Real JM; Hwa V; Pratt KL; Casamitjana R; Garcia-Gil MM; Rosenfeld RG; Ricart W
    Diabetes; 2006 Aug; 55(8):2333-9. PubMed ID: 16873698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids.
    Thamer C; Tschritter O; Haap M; Shirkavand F; Machann J; Fritsche A; Schick F; Häring H; Stumvoll M
    Horm Metab Res; 2005 Apr; 37(4):246-51. PubMed ID: 15952086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.
    Seppälä-Lindroos A; Vehkavaara S; Häkkinen AM; Goto T; Westerbacka J; Sovijärvi A; Halavaara J; Yki-Järvinen H
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3023-8. PubMed ID: 12107194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
    Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
    J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA
    Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.
    Bugianesi E; Pagotto U; Manini R; Vanni E; Gastaldelli A; de Iasio R; Gentilcore E; Natale S; Cassader M; Rizzetto M; Pasquali R; Marchesini G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3498-504. PubMed ID: 15797948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.
    Kotronen A; Juurinen L; Tiikkainen M; Vehkavaara S; Yki-Järvinen H
    Gastroenterology; 2008 Jul; 135(1):122-30. PubMed ID: 18474251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo.
    Yki-Järvinen H; Mäkimattila S; Utriainen T; Rutanen EM
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3227-32. PubMed ID: 7593430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity.
    Arafat AM; Weickert MO; Frystyk J; Spranger J; Schöfl C; Möhlig M; Pfeiffer AF
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5093-101. PubMed ID: 19846739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance.
    Shmueli E; Miell JP; Stewart M; Alberti KG; Record CO
    Hepatology; 1996 Jul; 24(1):127-33. PubMed ID: 8707251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.
    Heald AH; Kaushal K; Siddals KW; Rudenski AS; Anderson SG; Gibson JM
    Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):371-6. PubMed ID: 16915540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta insulin-like growth factor binding protein-1 (ΔIGFBP-1): a marker of hepatic insulin resistance?
    Borai A; Livingstone C; Heald AH; Oyindamola Y; Ferns G
    Ann Clin Biochem; 2014 Mar; 51(Pt 2):269-76. PubMed ID: 24056811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age.
    Hansen TK; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2002 May; 87(5):2185-93. PubMed ID: 11994362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.